{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:47:23Z","timestamp":1793836043590,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.eururo.2017.09.030","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T02:04:03Z","timestamp":1510020243000},"page":"543-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review"],"prefix":"10.1016","volume":"73","author":[{"given":"Mohammad","family":"Abufaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Horenblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.09.030_bib0355","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1111\/j.1464-410X.2012.11433.x","article-title":"Predictors of cancer-specific mortality after disease recurrence following radical cystectomy","volume":"111","author":"Rink","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.09.030_bib0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0365","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0370","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0375","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/tau.2016.08.23","article-title":"Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery","volume":"5","author":"Abufaraj","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers","volume":"63","author":"Kamat","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0385","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0390","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0395","first-page":"631","article-title":"Surgical resection of urological tumor metastases following medical treatment","volume":"109","author":"Heidenreich","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.eururo.2017.09.030_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.eururo.2017.09.030_bib0405","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-015-0839-y","article-title":"Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery","volume":"20","author":"Urakami","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0410","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ju.0000162018.40891.ba","article-title":"Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer","volume":"174","author":"Nieuwenhuijzen","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0415","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2013.08.082","article-title":"Induction chemotherapy followed by surgery in node positive bladder cancer","volume":"83","author":"Meijer","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.09.030_bib0420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2015.07.085","article-title":"A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy","volume":"195","author":"Zargar-Shoshtari","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0425","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0022-5347(05)66533-0","article-title":"Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0430","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urology.2008.07.035","article-title":"Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy","volume":"73","author":"Kassouf","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.09.030_bib0435","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1464-410X.2010.09574.x","article-title":"Induction chemotherapy for unresectable urothelial carcinoma of the bladder","volume":"107","author":"Ghadjar","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.09.030_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.08.012","article-title":"Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center experience","volume":"34","author":"Ho","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0445","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2016.67.5033","article-title":"Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0450","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-200101000-00015","article-title":"Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0455","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.1464-410X.2008.07877.x","article-title":"Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease","volume":"102","author":"Guzzo","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.09.030_bib0460","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.urolonc.2009.04.017","article-title":"Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer","volume":"29","author":"Yafi","year":"2001","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0465","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10147-011-0350-z","article-title":"Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?","volume":"18","author":"Bekku","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0470","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.athoracsur.2011.03.097","article-title":"Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?","volume":"92","author":"Matsuguma","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.eururo.2017.09.030_bib0475","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5090\/kjtcs.2012.45.4.242","article-title":"Result of surgical resection for pulmonary metastasis from urothelial carcinoma","volume":"45","author":"Han","year":"2012","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.eururo.2017.09.030_bib0480","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","article-title":"Is There a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience","volume":"171","author":"Siefker-radtke","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0485","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.eururo.2007.02.052","article-title":"Impact of multimodal treatment on survival in patients with metastatic urothelial cancer","volume":"52","author":"Abe","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0490","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","article-title":"Surgery for metastatic urothelial carcinoma with curative intent: The German Experience (AUO AB 30\/05)","volume":"55","author":"Lehmann","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0495","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1510\/icvts.2010.236687","article-title":"Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma","volume":"11","author":"Kanzaki","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.eururo.2017.09.030_bib0500","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.juro.2012.10.065","article-title":"Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy","volume":"189","author":"Nakagawa","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0505","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0510","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clgc.2015.04.013","article-title":"Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2017.09.030_bib0515","doi-asserted-by":"crossref","unstructured":"Luzzi L, Marulli G, Solli P, et al. Long-term results and prognostic factors of pulmonary metastasectomy in patients with metastatic transitional cell carcinoma. Thorac Cardiovasc Surg. In press. https:\/\/doi.org\/10.1055\/s-0036-1583271.","DOI":"10.1055\/s-0036-1583271"},{"key":"10.1016\/j.eururo.2017.09.030_bib0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0090-4295(00)00867-0","article-title":"Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial","volume":"57","author":"Otto","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.09.030_bib0525","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.ju.0000067601.29966.4a","article-title":"Is There a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?","volume":"169","author":"Sweeney","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0530","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejso.2008.07.001","article-title":"Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only","volume":"35","author":"de Vries","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2014.06.003","article-title":"Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2017.09.030_bib0540","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0545","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2006.07.1290","article-title":"Are nomograms better than currently available stage groupings for bladder cancer?","volume":"24","author":"Sternberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0550","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0555","doi-asserted-by":"crossref","first-page":"E272","DOI":"10.1111\/j.1464-410X.2010.09981.x","article-title":"Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy","volume":"108","author":"Kaag","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.09.030_bib0560","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.09.030_bib0565","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0570","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","article-title":"Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0575","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-5347(01)61921-9","article-title":"Pelvic lymph node dissection can be curative in patients with node positive bladder cancer","volume":"161","author":"Vieweg","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0580","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2017.09.030_bib0585","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/djt015","article-title":"Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy","volume":"105","author":"Apolo","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.09.030_bib0590","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00345-015-1631-3","article-title":"Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world","volume":"34","author":"Taguchi","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0595","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0600","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/iju.13031","article-title":"Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association","volume":"23","author":"Inokuchi","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0605","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.eururo.2012.01.049","article-title":"Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity","volume":"61","author":"Tarin","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0610","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2004.11.024","article-title":"Surgical factors influence bladder cancer outcomes: a cooperative group report","volume":"22","author":"Herr","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0615","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.juro.2007.05.160","article-title":"Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only","volume":"178","author":"Steven","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0620","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejso.2013.01.003","article-title":"Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience","volume":"39","author":"Meijer","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0625","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.eururo.2016.07.005","article-title":"The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016","volume":"70","author":"Bex","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0630","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.09.030_bib0635","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2016.68.3714","article-title":"Definitive management of primary bladder tumors in the context of metastatic disease: who, how, when, and why?","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0640","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0645","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0650","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","article-title":"Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma","volume":"17","author":"Dodd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0655","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11255-016-1226-y","article-title":"Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?","volume":"48","author":"Tonyali","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0660","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1016\/j.ejrad.2012.06.010","article-title":"Prospective evaluation of MRI, 11C-acetate PET\/CT and contrast-enhanced CT for staging of bladder cancer","volume":"81","author":"Vargas","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0665","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.ejrad.2011.07.018","article-title":"Clinical value of FDG PET or PET\/CT in urinary bladder cancer: A systemic review and meta-analysis","volume":"81","author":"Lu","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0670","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.ijrobp.2011.11.065","article-title":"Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer","volume":"83","author":"Yoshida","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0675","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2009.08.115","article-title":"Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer","volume":"183","author":"Shariat","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0680","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.09.030_bib0685","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0690","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.09.030_bib0695","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.09.030_bib0700","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817308400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817308400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T02:31:00Z","timestamp":1535250660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817308400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0302283817308400"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.09.030","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}